Wells Fargo
IBO

Wells Fargo’s Impact BioMedical IBO Stock Holding History

Wells Fargo’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134 Hold
224
– – ﹤0.01% 6481
2025
Q4 		$113 Sell
224
-29
-11% -$15 ﹤0.01% 6420
2025
Q3 		$168 Buy
253
+224
+772% +$141 ﹤0.01% 6355
2025
Q2 		$19 Sell
29
-1,000
-97% -$561 ﹤0.01% 6801
2025
Q1 		$895 Buy
1,029
+1,000
+3,448% +$1.73K ﹤0.01% 6245
2024
Q4 		$42 Hold
29
– – ﹤0.01% 6535
2024
Q3 		$58 Buy
+29
New +$69 ﹤0.01% 6335

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Wells Fargo's IBO Position: Q1 2026 in Review

Wells Fargo held its Impact BioMedical (IBO) position steady in Q1 2026 at 224 shares worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #6481.

Wells Fargo first reported a position in IBO in Q3 2024 and has held it in 7 quarters since. The position peaked at $895 in Q1 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Wells Fargo held 224 shares of Impact BioMedical worth $134 as of Q1 2026.
  • Wells Fargo left its Impact BioMedical share count unchanged in Q1 2026.
  • Impact BioMedical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6481 holding.
  • Wells Fargo first reported a position in Impact BioMedical in Q3 2024 and has held it in 7 quarters since.
  • Wells Fargo's Impact BioMedical position peaked at $895 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.